New study to monitor safety of Crohn's drug in kids
NCT ID NCT07564505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety of a drug called adalimumab in 30 Chinese children aged 6 to 17 with moderate-to-severe Crohn's disease. Researchers will track side effects over 12, 26, and 52 weeks of treatment. The goal is to understand how safe the drug is in real-world use for young patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN AGED 6 YEARS AND ABOVE WITH MODERATE - TO - SEVERE ACTIVE CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.